Sun Pharma Plans Rs 10,000 Crore Domestic Debt Sale to Refinance Organon Acquisition Loan

Sun Pharmaceutical Industries Ltd., India’s largest pharmaceutical company by market capitalisation, is preparing to issue approximately Rs 10,000 crore ($1.04 billion) in rupee-denominated bonds to take out part of the short-term debt raised for its overseas acquisition of Organon & Co., according to sources familiar with the matter.

The drugmaker is expected to issue bonds with shorter tenors spanning two, three, and four years. The proceeds will be deployed to partly refinance an 18-month bridge facility that Sun Pharma secured earlier this year to finance its multi-billion-dollar takeover of the U.S. healthcare firm.

Refinancing the Landmark Outbound Buyout

Sun Pharma agreed to acquire U.S.-listed Organon & Co. in an all-cash deal valued at nearly $12 billion, marking one of the largest outbound acquisitions ever undertaken by an Indian company. To fund the transaction, the pharmaceutical major closed an 18-month syndicated bridge loan backed by global and domestic lenders.

Key details of the acquisition financing structure:

• The overall acquisition was structured with commitments from major global institutions, including Citigroup Inc., JPMorgan Chase & Co., and Mitsubishi UFJ Financial Group Inc. (MUFG).
• State Bank of India (SBI), the nation's largest lender, joined the syndicate with a commitment of up to $1 billion following regulatory changes permitting domestic commercial banks to back corporate acquisitions.
• The bridge loan served as interim financing designed to be taken out through longer-term capital market debt and internal accruals.

Tapping the Domestic Bond Market

Sun Pharma's decision to tap the Indian rupee bond market highlights a broader shift among Indian conglomerates toward domestic credit. With U.S. Treasury yields lingering near multi-year highs, cross-border dollar debt has become increasingly expensive. In contrast, deep liquidity in India's onshore market offers attractive pricing for top-tier corporate issuers.

Corporate treasuries are also moving swiftly to lock in borrowing costs ahead of potential monetary policy realignments by the Reserve Bank of India. Domestic corporate bond sales have accelerated sharply, with multi-billion-dollar issuances lined up as companies replace high-cost foreign currency liabilities with rupee debt.

Balance Sheet Impact for Indian Investors

Historically known for maintaining a net-cash balance sheet, Sun Pharma's debt-funded purchase of Organon marks a strategic shift to scale its global presence in women's health and specialty biosimilars. While the transaction has added leverage, analysts and rating agencies have highlighted the combined entity's robust cash flow generation as a strong buffer.

The planned Rs 10,000 crore bond issuance will systematically lengthen Sun Pharma’s debt maturity profile and reduce interest-rate volatility on the bridge facility. For the Indian debt market, the placement offers institutional participants like mutual funds, insurance companies, and pension trusts access to highly rated corporate paper from a leading blue-chip corporate borrower.

Tags: Sun Pharma Organon State Bank of India Reserve Bank of India Corporate Debt Nifty Pharma